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Abstract
Background: The metastatic disease rather than the primary tumor itself is responsible for death
in most solid tumors, including breast cancer. The role of matrix metalloproteinases (MMPs), tissue
inhibitors of MMPs (TIMPs) and Reversion-inducing cysteine-rich protein with Kazal motifs (RECK)
in the metastatic process has previously been established. However, in all published studies only a
limited number of MMPs/MMP inhibitors was analyzed in a limited number of cell lines. Here, we
propose a more comprehensive approach by analyzing the expression levels of several MMPs
(MMP-2, MMP-9 and MMP-14) and MMP inhibitors (TIMP-1, TIMP-2 and RECK) in different models
(five human breast cancer cell lines, 72 primary breast tumors and 30 adjacent normal tissues).
Methods: We analyzed the expression levels of MMP-2, MMP-9 and MMP-14 and their inhibitors
(TIMP-1, TIMP-2 and RECK) by quantitative RT-PCR (qRT-PCR) in five human breast cancer cell
lines presenting increased invasiveness and metastatic potential, 72 primary breast tumors and 30
adjacent normal tissues. Moreover, the role of cell-extracellular matrix elements interactions in the
regulation of expression and activity of MMPs and their inhibitors was analyzed by culturing these
cell lines on plastic or on artificial ECM (Matrigel).
Results: The results demonstrated that MMPs mRNA expression levels displayed a positive and
statistically significant correlation with the transcriptional expression levels of their inhibitors both
in the cell line models and in the tumor tissue samples. Furthermore, the expression of all MMP
inhibitors was modulated by cell-Matrigel contact only in highly invasive and metastatic cell lines.
The enzyme/inhibitor balance at the transcriptional level significantly favors the enzyme which is
more evident in tumor than in adjacent non-tumor tissue samples.
Conclusion: Our results suggest that the expression of MMPs and their inhibitors, at least at the
transcriptional level, might be regulated by common factors and signaling pathways. Therefore, the
multi-factorial analysis of these molecules could provide new and independent prognostic
information contributing to the determination of more adequate therapy strategies for each
patient.
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Background
Among diverse cancer types, breast carcinoma stands out
for its increasing incidence rates and high mortality
worldwide [1]. Like most solid tumors, metastatic disease
rather than the primary tumor itself is responsible for
death [2-4]. The metastatic process involves a complex
cascade of events, including the organized breakdown of
the extracellular matrix (ECM) by matrix metalloprotein-
ases (MMPs) [5,6]. Together, the MMPs are able to process
or degrade all ECM components. Each ECM element is
cleaved by a specific MMP or MMP group [7]. The activity
of these proteases is tightly regulated by specific inhibi-
tors, known as tissue inhibitors of MMPs (TIMPs) [7,8].
Consistent with their role in tumor progression, high lev-
els of a number of MMPs have been shown to correlate
with poor prognosis in human cancers [9-11]. Surpris-
ingly, high levels of TIMP-1 and TIMP-2 have also been
shown to predict adverse prognosis and correlate with
tumor aggressiveness in several different human cancers,
including breast cancer [12-14]. TIMPs expression profile
could be the result of its action as a multifunctional mol-
ecule [8].
The RECK metastasis suppressor gene was isolated by
screening a fibroblast expression library for cDNAs that
induced flat revertants in ν-Ki-ras-transformed NIH3T3
cells [15]. RECK encodes a membrane-associated MMP
regulator protein that is able to suppress tumor invasion
and metastasis by negatively regulating MMPs involved in
carcinogenesis, namely: MMP-2, MMP-9 and MMP-14
(MT1-MMP) [16,17]. Due to these functions, RECK has
been described as a good prognosis marker in several
tumor types, including breast carcinomas [18,19].
The ECM degradation and, consequently, the invasive and
metastatic potential of tumor cells is the result of the
umbalance between the activities of these multiple factors
that compose the proteases/inhibitors equilibrium [20].
Furthermore, each one of these molecules is involved in
different stages and processes during tumor progression
[20,21]. Although the expression and activity profile of
MMPs, TIMPs and RECK have already been described in
several cell line models [22-24], few reports analyze more
than one MMP or MMP inhibitor in different cell lines at
the same time, using the same approach [23]. Thus, there
are no studies which address the complexity of MMPs/
inhibitors system in a multi-factorial context. Moreover,
there are no reports comparing expression profiles of
these important modulators of the metastatic process, in
both a cell line model system and in breast tumor tissue
samples.
Here, we analyzed the expression levels of MMPs and their
inhibitors, by qRT-PCR, in a panel of five human breast
cancer cell lines displaying different degrees of invasive-
ness and metastatic potential and in 72 primary breast
cancer and 30 adjacent non-tumor tissue specimens. The
results demonstrate a significant and positive correlation
between the levels of MMPs and their inhibitors both in
the cell line models and in tumor tissue samples, suggest-
ing that the expression of these molecules, at least at the
transcriptional level, might be regulated by common fac-
tors and signaling pathways. Therefore, deregulation of
only one of these components could be followed by alter-
ations of several other members of the proteases/inhibi-
tors families. Therefore, we suggest that a multi-factorial
analysis is crucial to properly evaluate metastasis.
Methods
Cell Culture and RNA extraction
Five human breast cancer cell lines displaying different
degrees of invasiveness and metastatic potential were used
in this study (Table 1). 104cell/cm2 were seeded onto
uncoated or Matrigel-coated plastic dishes and incubated
for 3 or 5 days. Cells were lysed in 4 M guanidine thiocy-
anate; 25 mM sodium citrate (pH 7.0); 0.1 M β-mercap-
toethanol) and the lysate was placed on top a Cesium
chloride cushion [5.7 M cesium chloride, 25 mM sodium
acetate (pH 5.0)]. Samples were ultracentrifuged
(100,000 g, at 20°C for 18 h); the RNA pellet was solubi-
lized in Milli-Q H2O and stored at -70°C. The RNA qual-
ity was evaluated by electrophoresis in agarose gel
containing 20 mM guanidine thiocyanate.
Table 1: General characteristics of previously described human breast cancer cell lines
Cell Line Histopathologycal type Origin ER PR Invasive potential Metastatic potencial
MCF-7 Invasive ductal carcinoma Metastasis (pleural effusion) + + + --
ZR-75-1 Invasive ductal carcinoma Metastasis (ascite) + + ++ --
MDA-MB-435 Invasive ductal carcinoma Metastasis (pleural effusion) - - +++ ++++
MDA-MB-231 Invasive ductal carcinoma Metastasis (pleural effusion) - - ++++ +
Hs578T Carcinosarcoma Tumor primary - - ++++ ++++
Table based on previously published data [39–41].
ER: status of estrogen receptor; PR: status of progesterone receptor (Negative (-), Positive (+)).
aInvasive potential analyzed by chemoinvasion assays through of reconstituted basal lamina (Matrigel) in transwell plates.
bMetastatic potential verified through of spontaneous metastasis assays in immune deficient miceBMC Cancer 2009, 9:20 http://www.biomedcentral.com/1471-2407/9/20
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Patients
The tumor and adjacent non-tumor breast tissue samples
used in this study were provided by the Tumor Bank of the
A.C. Camargo Cancer Hospital and Alfredo Abrão Cancer
Hospital. The study protocol was approved by the Ethics
Committee of these hospitals, certifying these studies
were conducted in accordance with the guidelines of the
1975 Declaration of Helsinki (Process number 20 of June
24th, 2006). Informed consent was obtained from all
patients before or after surgery. All of these tissue frag-
ments were obtained during mastectomy by cold scalpel.
The adjacent non-tumor tissue was removed at least 4 cm
from the tumor border. All tissue samples were dissected
by a pathologist, with the help of magnifying glasses, dur-
ing surgery. The samples were harvested by the patholo-
gist and immediately transferred to liquid nitrogen. These
frozen samples were processed for RNA extraction, after
informed consent was obtained from the patients. The
methodology used for RNA extraction from tissue speci-
mens was that previously described for RNA extraction
from cell culture. The RNA quality was evaluated by elec-
trophoresis in agarose gel containing 20 mM guanidine
thiocyanate. The RNA samples were quantified and simi-
lar quantities were used for cDNA synthesis. Of these, 11
(15.3%) were coded as stage I, 16 (22.2%) as stage IIA, 20
(27.8%) as stage IIB, 9 (12.5%) as stage IIIA, 11 (15.3%)
as stage IIIB and 5 (6.9%) as stage IV. Lymph nodes were
evaluated in these tumors samples: 41 (56.9%) displayed
compromised lymph nodes. The status of the molecular
markers estrogen receptor (ER) and progesterone receptor
(PR) was analyzed in 56 tumors, of which 41 tumors
(73.2%) were positive for ER and 30 (53.6%) for PR.
These and other clinical pathological data are shown in
the Additional Data (see Additional file 1).
Quantitative RT-PCR
For cDNA synthesis, 1 μg of total RNA was reverse-tran-
scribed using oligo-dT, random primers and Superscript
Amplification System (Invitrogen). Quantitative RT-PCR
was carried out using SYBR Green PCR Master Mix
(Applied Biosystems). Table 2 shows the primers used,
with the optimal concentration (in range of 100 nM to
600 nM). Cycling conditions were 50°C for 2 min, 95°C
for 10 min followed by 10 cycles of 95°C for 15 sec and
60°C for 30 sec. For quantification, the target genes were
normalized to the internal standard GAPDH, HPRT, β-
actin and β-tubulin genes. The amplification efficiency
analyzed was calculated for each gene from the given
slope in linear regression curve of Ct values versus log of
cDNA concentration. The corresponding PCR efficiency
(E) of one cycle in the exponential phase was calculated
according to the equation: E = 10[-1/slope]. Relative expres-
sion levels were calculated according to the previously
described Pfaffl model [25].
Zymography
Gelatin zymography was used to analyze MMP-2 and
MMP-9 protease activities in human breast cancer cell
lines (Table 1). 5 × 104cell/cm2 was seeded onto plastic or
Matrigel-coated plastic dishes. After 48 h, cultures were
washed and replenished with their respective serum-free
ATCC-recommended culture medium plus 0.1% BSA
(Sigma) for 72 h. The protein content of the serum-free
conditioned medium (CM) was measured using the Brad-
ford method. 25 μg of protein of each CM were mixed
with SDS sample buffer without reducing agent and
heated at 50°C for 10 sec. Samples were resolved in 12%
polyacrylamide gels copolymerized with 0.1% gelatin
(Bio-Rad). After electrophoresis, gels were washed in 2%
(v/v) Triton X-100 for 15 min at 37°C to remove SDS, and
then incubated in developing buffer [50 mM Tris-HCl
(pH 7.4), 10 mM CaCl2 and 5 μM ZnCl2] for 16–20 h at
37°C. Subsequently, gels were fixed and stained with 30%
methanol and 10% glacial acetic acid containing 0.5%
Coomassie blue R250 (Sigma). The protease activity was
visualized as clear bands within the stained gel.
Statistical Analysis
All statistical analyses were performed with the GraphPad
Prism 4.0 program. Results are presented as mean ± stand-
ard deviation. Statistical significance was determined
using Student's t test for analysis of only two populations.
One way ANOVA variance analysis and Tukey-Kramer test
were used to calculate p-values for multiple comparisons.
Pearson correlation test was used for correlation analysis.
The Chi-square test was used in analysis of quantitative
Table 2: Sequence of primers used
Gene Primer sequence
MMP-2 F: AGCTCCCGGAAAAGATTGATG
R: CAGGGTGCTGGCTGAGTAGAT
MMP-9 F: CCTGGAGACCTGAGAACCAATC
R: GATTTCGACTCTCCACGCATCT
MMP-14 F: GCAGAAGTTTTACGGCTTGCA
R: TCGAACATTGGCCTTGATCTC
TIMP-1 F: CCGCAGCGAGGAGTTTCTC
R: GAGCTAAGCTCAGGCTGTTCCA
TIMP-2 F: CGACATTTATGGCAACCCTATCA
R: GCCGTGTAGATAAACTCTATATCC
RECK F: TGCAAGCAGGCATCTTCAAA
R: ACCGAGCCCATTTCATTTCTG
GAPDH F: ACCCACTCCTCCACCTTTGA
R: CTGTTGCTGTAGCCAAATTCGT
b-tulin F: TCAACACCTTCTTCAGTGAAACG
R: AGTGCCAGTGCGAACTTCATC
b-actin F: GGCACCCAGCACAATGAAG
R: CCGATCCACACGGAGTACTTG
HPRT F: GAACGTCTTGCTCGAGATGTGA
R: TCCAGCAGGTCAGCAAAGAATBMC Cancer 2009, 9:20 http://www.biomedcentral.com/1471-2407/9/20
Page 4 of 11
(page number not for citation purposes)
variable association. Differences were considered signifi-
cant at p < 0.05.
Results
mRNA expression and activity of MMPs and their 
inhibitors in human breast cancer cell lines
In order to determine whether MMPs and their inhibitors
are responsible for the different invasive and metastatic
capacities displayed by a panel of five human breast can-
cer cell lines (Table 1), we analyzed the expression levels
of MMPs, TIMPs and RECK by qRT-PCR. The results (Fig.
1) demonstrated that the relative levels of MMP-2, MMP-
9, MMP-14, TIMP-1, TIMP-2 and RECK were generally
higher in highly invasive and metastatic cell lines (MDA-
MB-435, MDA-MB-231 and Hs578T), when compared to
less aggressive ones (MCF-7 and ZR-75-1). The levels of
MMP-2 and MMP-14 were significantly elevated (p <
0.001) in the Hs578T cell line relative to those of less
aggressive cell lines. The MDA-MB-231 cell line displayed
significantly higher mRNA levels of MMP-9 and MMP-14
Expression levels of MMPs (A) and their inhibitors (B) by qRT-PCR using total RNA from a panel of five human breast cancer  cell lines, displaying increased degrees of invasiveness and metastatic potential, cultured on different substrates (plastic or  Matrigel) Figure 1
Expression levels of MMPs (A) and their inhibitors (B) by qRT-PCR using total RNA from a panel of five human 
breast cancer cell lines, displaying increased degrees of invasiveness and metastatic potential, cultured on dif-
ferent substrates (plastic or Matrigel). GAPDH was used to normalize the values. Results are presented as MEANS ± SD 
of two independent experiments. P values were derived from One-way analysis of variance and Tukey-Kramer test. *, p < 0.05; 
**, p < 0.01 and ***p < 0.001, all versus control (MCF-7).BMC Cancer 2009, 9:20 http://www.biomedcentral.com/1471-2407/9/20
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than MCF-7 (p < 0.001). In most cases, the MDA-MB-435
cell line showed a similar tendency, but it was not statisti-
cally significant. Moreover, all analyzed MMPs inhibitor
(TIMP-1, TIMP-2 and RECK) are also over-expressed in
MDA-MB-435, MDA-MB-231 and Hs578T breast cancer
cells. The TIMP-1 gene expression was significantly higher
in MDA-MB-435 than MCF-7 (p < 0.01). The others ana-
lyzed MMP inhibitors (TIMP-2 and RECK) displayed stat-
ically significant increased mRNA expression levels in all
highly invasive and metastatic cell lines used in this study
when compared with MCF-7 (p < 0.001, except to TIMP-2
expression in Hs578T whose statistical significance was p
< 0.01.
Given that cell-ECM interaction regulates gene expression,
we investigated the possible role of this interaction in the
control of expression and activity of MMPs and their
inhibitors. We cultured these human breast cancer cell
lines on plastic or on artificial ECM (Matrigel) and then
assessed MMPs and their inhibitors expression and activ-
ity. Among MMPs, only MMP-2 expression was signifi-
cantly regulated by cell-ECM interaction, and only in
MDA-MB-435 (p < 0.05) and MDA-MB-231 (p < 0.01)
lines (Fig. 1A). However, the gelatinolytic activities of
MMP-2 and MMP-9 are significantly higher in cells cul-
tured on Matrigel than those seeded on uncoated plastic
(Fig. 2). MDA-MB-231 and Hs578T cell lines displayed
higher MMP activity than less invasive and metastatic
breast cancer cell lines. The expression of all analyzed
MMP inhibitors was modulated by cell-Matrigel contact
in highly invasive and metastatic cell lines (MDA-MB-231
and Hs578T) (Fig. 1B). In almost all cases, the expression
of these MMP inhibitors was not regulated by Matrigel.
The results presented in Fig. 1 were obtained with cells
cultured for five days on plastic or Matrigel. The same
results were observed when cells were cultured for three
days (data not shown). The relative mRNA expression
data was normalized using two different housekeeping
genes, namely: β-tubulin and GAPDH, and similar expres-
sion profiles were obtained.
Correlation between mRNA expression of MMPs and their 
inhibitors in human breast cancer cell lines
We evaluated whether a correlation between mRNA
expression levels of MMPs and their inhibitors exists in
the cell model of tumor progression used in this study.
The gene expression values displayed by these five human
breast cancer cell lines cultured either on plastic or
Matrigel for 3 or 5 days, obtained by qRT-PCR, were sub-
jected to statistical analysis using Pearson correlation test.
Representative zymogram of gelatin zymography analysis to detect the activity of secreted MMP-2 and MMP-9 (three independ- ent experiments) using conditioned medium from a panel of human breast cancer cell lines, displaying increased degrees of  invasiveness and metastatic potential, cultured on different substrates (plastic or Matrigel) Figure 2
Representative zymogram of gelatin zymography analysis to detect the activity of secreted MMP-2 and MMP-
9 (three independent experiments) using conditioned medium from a panel of human breast cancer cell lines, 
displaying increased degrees of invasiveness and metastatic potential, cultured on different substrates (plastic 
or Matrigel).BMC Cancer 2009, 9:20 http://www.biomedcentral.com/1471-2407/9/20
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The results demonstrate a positive and significant correla-
tion between the relative expression levels of all analyzed
MMPs and MMP inhibitors. The expression of MMP-2 was
an exception, since it significantly correlated only with
MMP-14, TIMP-1 and RECK expression (Table 3).
mRNA expression levels of MMPs and their inhibitors in 
samples of primary breast tumors and adjacent non-tumor 
tissues
In order to validate the data obtained from breast cancer
cell lines (Fig. 1), 72 samples of invasive ductal breast car-
cinomas and 30 samples of adjacent non-tumor tissues
were selected and analyzed by qRT-PCR. The results (Fig.
3) demonstrate that the relative expression levels of MMP-
2 and MMP-14 of tumor samples were significantly higher
than those of adjacent non-tumor tissue (p = 0.0202 and
p < 0.0001, respectively). Furthermore, the samples
derived from tumors showed a higher MMP-9 expression
tendency than the adjacent non-tumor tissue specimens.
TIMP-1 and TIMP-2 gene expression levels were signifi-
cantly lower in tumors than in adjacent non-tumor tissue
samples (p = 0.0169 and p = 0.0127, respectively). A sim-
ilar trend was verified for RECK expression levels. These
results were normalized using two different housekeeping
genes (β-actin and HPRT), yielding similar expression
profiles.
Balance between relative gene expression levels of MMPs 
and their inhibitors in samples of primary breast tumors 
and adjacent non-tumor tissues
The differences in the enzyme/inhibitor balance between
tumor tissue specimens and adjacent non-tumor tissue
samples were evaluated by calculating the MMPs/MMP
inhibitors ratio values by using the mRNA expression lev-
els data obtained by qRT-PCR. The results indicated that
the ratios between MMP-2/RECK, MMP-9/RECK and
MMP-14/RECK were significantly higher in the tumor
than in adjacent non-tumor tissue samples (p = 0.0024, p
= 0.0001 and p < 0.0001, respectively) (Figure 4). The
same results were obtained for the ratios between MMP-9/
TIMP-1, MMP-2/TIMP-2, MMP-14/TIMP-1 and MMP-14/
TIMP-2 (p = 0.0271, p = 0.0012, p < 0.0001 and p <
0.0001, respectively). The same was obtained for the ratio
between the sum of relative expression values of all MMPs
(MMP-2, MMP-9 and MMP-14) and MMPs inhibitors
(TIMP-1, TIMP-2 and RECK) (p < 0.0001)
Correlation between MMPs, TIMPs and RECK expression 
and clinical-pathological variables in human breast 
carcinomas
The association of relative mRNA expression levels of
MMPs, TIMPs and RECK with clinical-pathological data
was statistically verified by Chi-Square test. MMP expres-
sion showed no significant association with the clinical
data evaluated in this study (see Additional Data). The PR
status presented a significant association with TIMP-1
gene expression (p = 0.020) (data not shown). Statistically
significant associations were not observed between the
relative expression of either TIMP-2 or RECK and the clin-
ical variables analyzed.
The values of relative gene expression of MMPs and their
inhibitors from breast tumor tissue samples were sub-
jected to Pearson's test for correlation. The expression lev-
els of TIMP-2 and RECK in tumoral samples showed a
significant positive correlation with the gene expression of
MMP-2 and MMP-14 (Table 4) (p < 0.0001 for all these
correlations).
Discussion
Development of metastasis is the most critical parameter
for determination of survival in breast cancer patients.
Patients diagnosed and treated before further extension of
the tumor present higher cure rate [2-4]. The role of MMPs
and their specific inhibitors in the metastatic process is
well established. Nowadays, there are more than 20
MMPs identified in humans, and several MMP inhibitors,
each one of these molecules being involved in different
steps of tumor progression [20,21]. In spite of the com-
plexity of MMPs/MMP inhibitors system, all previous
studies which analyzed the status of these molecules dur-
ing mammary tumor progression only focused on a small
Table 3: Correlation between MMPs and their inhibitors in 
human breast cancer cell lines
Pearson Correlation Test R p-value n
MMP-2 MMP-9 -0.17 p = 0.1625 69
MMP-14 0.47 p < 0.0001 72
TIMP-1 0.25 p = 0.0346 72
TIMP-2 0.10 p = 0.3979 69
RECK 0.44 p < 0.0001 72
MMP-9 MMP-14 0.75 p < 0.0001 70
TIMP-1 0.36 p = 0.0022 71
TIMP-2 0.52 p < 0.0001 67
RECK 0.32 p = 0.0059 71
MMP-14 TIMP-1 0.52 p < 0.0001 75
TIMP-2 0.67 p < 0.0001 70
RECK 0.67 p < 0.0001 74
TIMP-1 TIMP-2 0.68 p < 0.0001 71
RECK 0.66 p < 0.0001 75
TIMP-2 RECK 0.80 p < 0.0001 70
Correlations between gene expressions data were calculated using 
Pearson Correlation test.
(n) Number of analyzed samples
(r) Pearson correlation coefficientBMC Cancer 2009, 9:20 http://www.biomedcentral.com/1471-2407/9/20
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number of MMPs/MMP inhibitors in a limited number of
models. Here, we proposed a more extensive approach by
analyzing the mRNA expression levels of different MMPs
(MMP-2, MMP-9 and MMP-14) and MMP inhibitors by
qRT-PCR (TIMP-1, TIMP-2 and RECK) in several models
(five human breast cancer cell lines, 72 primary breast
tumors and 30 adjacent normal tissues).
The verified mRNA expression levels, obtained by qRT-
PCR, suggested that breast cancer progression from pre-
malignant stages to highly invasive and metastatic carci-
nomas could be accompanied by increased expression of
MMPs and their inhibitors. The total RNA from a panel of
five human breast cancer cell lines, displaying increased
degrees of invasiveness and metastatic potential, were
used to perform this quantitative RT-PCR assay. In the cell
model used, the levels of all analyzed MMPs (MMP-2,
MMP-9 and MMP-14) were, in almost all cases, higher in
cell lines with elevated invasive and metastatic capacities
(MDA-MB-435, MDA-MB-231 and Hs578T) when com-
pared to less aggressive ones (MCF-7 and ZR-75-1). These
results corroborate the data previously obtained by other
groups, in which MMPs expression in breast cancer cell
models positively correlates with a highly aggressive phe-
notype [26,27]. We found similar mRNA expression pro-
files for all analyzed MMP inhibitors (TIMP-1, TIMP-2
and RECK). At first sight, these results seem contradictory,
since these molecules were described as MMP inhibitors.
However, elevated mRNA expression levels of TIMP-1 and
TIMP-2 have been previously detected in breast cancer cell
lines with high invasive and metastatic potential [28]. Fur-
thermore, several reports describe TIMPs as multifunc-
Expression levels of MMPs and their inhibitors by qRT-PCR Figure 3
Expression levels of MMPs and their inhibitors by qRT-PCR. It was performed using total RNA from samples of pri-
mary breast tumors and adjacent normal border. β-actin was used to normalize the values. The statistical significance was 
determined using Student's t test.BMC Cancer 2009, 9:20 http://www.biomedcentral.com/1471-2407/9/20
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tional molecules [8]. Thus, these molecules were both
able to suppress and to promote tumor progression [8].
On the other hand, high expression levels of RECK, a
membrane-associated MMP regulator protein, which is
able to suppress tumor invasion and metastasis, were
associated with better prognosis in several types of tumor,
including breast carcinomas [18,19]. However, our results
demonstrate that RECK mRNA expression level is
increased during breast cancer progression. Thus, at first
sight, these data seem to be at variance with the previous
studies, suggesting that increased RECK levels could be
associated not with better prognosis, but with late clinical
stages. Nevertheless, other reports demonstrated that ele-
vated levels of RECK were associated with better prognosis
only for patients in late clinical stages [29,30]. Therefore,
tumors that present overexpression of RECK could display
a better clinical course, depending on the enzyme/inhibi-
tor context. Thus, induction of RECK gene expression,
observed during breast cancer progression, could be a cel-
lular response to enhanced expression and activity of
MMPs. In this context, the ECM proteolysis equilibrium
could be maintained by re-establishment of the MMPs/
inhibitors balance.
The role of cell-ECM elements interaction in regulation of
expression and activity of these molecules was evaluated.
The gelatin degradation ability of MMP-2 and MMP-9,
evaluated by zymography assays, was significantly
increased in cultures seeded onto Matrigel, when com-
pared to those seeded onto uncoated plastic. Moreover, in
highly aggressive cell lines, enhanced MMP activity was
Analysis of the proteinase/inhibitor balance at transcriptional levels by qRT-PCR using total RNA from samples of primary  breast tumors and adjacent normal border Figure 4
Analysis of the proteinase/inhibitor balance at transcriptional levels by qRT-PCR using total RNA from sam-
ples of primary breast tumors and adjacent normal border. β-actin was used to normalize the values. The statistical 
significance was determined using Student's t test.BMC Cancer 2009, 9:20 http://www.biomedcentral.com/1471-2407/9/20
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observed in less invasive and metastatic breast cancer
cells, corroborating the data obtained in mRNA expres-
sion analysis. However, among the analyzed proteases,
only MMP-2 expression was significantly modulated by
cell-ECM elements interaction. These results suggest that
increased proteolytic activity is independent of transcrip-
tional activation, corroborating previously published data
[31]. Our results demonstrate that the transcript levels of
all studied MMP inhibitors are significantly modulated by
the reconstituted basal lamina. This regulation of TIMP-1,
TIMP-2 and RECK mRNA levels by cell-Matrigel contact
was significant only in highly invasive and metastatic cell
lines. Therefore, the intense ECM degradation is corre-
lated with increased MMP inhibitor expression. The ECM
supplies mechanical support to cells and structural integ-
rity to tissues [6,32]. Furthermore, ECM performs an
instructive role, since it is a reservoir of cytokines, and of
growth and differentiation factors, which can be dis-
charged and/or activated during proteolysis of ECM ele-
ments [33] by MMPs, contributing to the crosstalk
between tumor cells and the microenvironment [34].
Therefore, the high mRNA expression levels of MMP
inhibitors, found in highly aggressive cell lines, probably
reflects a cellular reaction mechanism to intense ECM
remodeling, as previously discussed. Thus, during ECM
degradation, an important factor involved in induction of
TIMPs and RECK can be discharged and/or activated. Our
results corroborate this hypothesis, since we demon-
strated that ECM is important only in modulation of gene
expression of MMP inhibitors and, moreover, only in
highly invasive and metastatic cell lines. Therefore, we
suggest that this negative feedback mechanism of induc-
tion of protease inhibitors, during breast cancer progres-
sion, occurs for the re-establishment of the MMP/
inhibitors balance and, consequently, for homeostasis of
ECM proteolysis.
Cellular models are commonly used in Cell and Molecu-
lar Biology studies due to the limited source of tissue sam-
ples. However, enrichment for malignant cells and
absence of stroma may compromise comparisons
between cell lines and tumors [35]. Therefore, to discard
possible cell culture artifacts, we also analyzed the expres-
sion of MMPs and their inhibitors in primary breast can-
cer tumor samples by qRT-PCR. The results obtained
demonstrate, in a more general scenario, that the mRNA
expression levels of MMPs are significantly higher in
tumor samples than in adjacent non-tumor tissues. On
the other hand, TIMP-1, TIMP-2 and RECK gene expres-
sion levels were significantly lower in tumors when com-
pared with adjacent normal tissues. Furthermore, our
results demonstrate a significant positive correlation
between the gene expression levels of these proteases and
their inhibitors in primary breast tumors from patients.
Therefore, we suggest that increased expression of genes
responsible for ECM degradation is coordinately accom-
panied by increased expression of their specific inhibitors
and that the levels of MMPs, TIMPs and RECK transcripts
may be regulated by common factors and signaling path-
ways.
Corroborating other studies in breast cancer [10,36], we
found no significant association between the mRNA
expression levels of the MMPs analyzed and clinical-path-
ological data [10,36]. These results suggest that the MMPs
may supply independent prognostic information. How-
ever, there are conflicting results on the prognostic value
of these proteases in this model. These differences can, at
least in part, be due to the different methodologies used
and to possible modulation of MMPs by adjuvant sys-
temic treatment [37,38]. Furthermore, the TIMP-1, TIMP-
2 and RECK transcript levels did not correlate with the
clinical parameters from patients. The status of PR was an
exception, which showed a significant correlation with
TIMP-1 gene expression only. Likewise, we suggest that
expression of the analyzed MMPs inhibitors may supply
independent prognostic information.
Conclusion
Taken together, the results obtained demonstrate that
MMPs and their specific inhibitors are overexpressed in
more aggressive breast cancer cell lines. However, it is
likely that each one of these molecules plays distinct roles
in acquisition of the invasive and metastatic capacity. This
Table 4: Correlation between expression of MMPs and their 
inhibitors in samples of primary breast tumors
Pearson Correlation Test r p-value N
MMP-2 MMP-9 0.06 p = 0.6523 67
MMP-14 0.68 p < 0.0001 70
TIMP-1 -1.3 p = 0.2968 70
TIMP-2 0.65 p < 0.0001 70
RECK 0.64 p < 0.0001 70
MMP-9 MMP-14 0.17 p = 0.1586 67
TIMP-1 0.07 p = 0.6005 67
TIMP-2 0.21 p = 0.0925 67
RECK 0.04 p = 0.7245 67
MMP-14 TIMP-1 -1.7 p = 0.1474 70
TIMP-2 0.61 p < 0.0001 70
RECK 0.49 p < 0.0001 70
TIMP-1 TIMP-2 0.06 p = 0.6375 70
RECK -1.3 p = 0.2702 70
TIMP-2 RECK 0.42 p = 0.0003 70
Correlations between gene expressions data were calculated using 
Pearson Correlation test.
(n) Number of analyzed samples
(r) Pearson correlation coefficientBMC Cancer 2009, 9:20 http://www.biomedcentral.com/1471-2407/9/20
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complexity of the MMPs-inhibitors system is intensified
by a strong correlation found between the expression lev-
els of these key regulators of the metastatic process. Thus,
we suggest that the expression analysis of only one of
these molecules or the independent quantification of
these molecular markers does not provide sufficient infor-
mation to elucidate the pathological proteolytic mecha-
nisms associated with the tumor. Therefore, simultaneous
analysis of the expression status of these molecules could
be a better parameter to determine the most adequate
therapy for each patient.
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